2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Treatment with crizotinib (Xalkori) demonstrated an overall response rate (ORR) of 72% in patients with ROS1-rearranged nonâ€“small cell lung cancer (NSCLC), according to phase I data presented at the 2014 ESMO Congress and published in The New England Journal of Medicine.
Alice T. Shaw, MD, PhD
Treatment with crizotinib (Xalkori) demonstrated an overall response rate (ORR) of 72% in patients with ROS1-rearranged non—small cell lung cancer (NSCLC), according to phase I data presented at the 2014 ESMO Congress and published in The New England Journal of Medicine.
“Prior to this study, there were a handful of reports describing marked responses to crizotinib in individual patients with ROS1-positive lung tumors,” lead author Alice T. Shaw, MD, PhD, from the Massachusetts General Hospital Cancer Center, said in a statement. “This is the first definitive study to establish crizotinib’s activity in a large group of patients with ROS1-positive lung cancer and to confirm that ROS1 is a bona fide therapeutic target in those patients.”
In the phase I trial, 50 patients at a median age of 53 were treated with crizotinib at 250 mg twice daily in a continuous 28-day cycle. A majority of patients had an ECOG performance status of 0 or 1 (98%), had never smoked (78%), and had adenocarcinoma histology (98%).
ROS1 rearrangements were confirmed in all but one patient using a break-apart FISH test, with the remaining patient identified by RT-PCR. The majority of patients (86%) had received previous treatment, with 44% having received more than 1 prior therapy.
The ORR of 72% was comprised of 3 complete responses (6%) and 33 partial responses (66%). The median time to first response was 7.9 weeks and the median duration of response was 17.6 months. Nine patients (18%) had stable disease following treatment. At the time of the analysis, 64% of patients were still responding to therapy.
The median progression-free survival (PFS) with crizotinib was 19.2 months. At a median follow-up for overall survival (OS) of 16.4 months, the 12-month OS rate was 85%. The median had not been reached.
Crizotinib’s safety profile was similar to previous studies in patients with ALK-rearranged NSCLC, the authors noted. The most common events with crizotinib were visual impairment (82%), diarrhea (44%), nausea (40%), peripheral edema (40%), constipation (34%), vomiting (34%), an elevated aspartate aminotransferase level (22%), fatigue (20%), dysgeusia (18%), and dizziness (16%).
The most common grade 3 adverse events were hypophosphatemia (10%), neutropenia (10%), and an elevated alanine aminotransferase level (4%). Additionally, one patient (2%) discontinued crizotinib because of treatment-related nausea.
The FDA granted an accelerated approval to crizotinib as a treatment for patients with ALK-rearranged NSCLC in 2011, based on an ORR of up to 61%. In November 2013, a full approval was granted to the drug following the demonstration of improvement in PFS and ORR when compared with chemotherapy.
While crizotinib is not currently approved as a treatment for patients with ROS1-rearranged NSCLC, evidence from a variety of studies has eluded to its efficacy in this space. In fact, NCCN guidelines recommend treatment with crizotinib for patients with advanced NSCLC who harbor a ROS1 rearrangement, which occurs in approximately 1% of patients.
“This is a great example of success in personalized medicine," senior study author John Iafrate, MD, PhD, medical director of the Massachusetts General Hospital Center for Integrated Diagnostics, said in a statement. "While NSCLC patients with ROS1 fusions are rare, if you devote the diagnostic laboratory resources to find that 1 to 2 percent of patients, you will make a real difference.”
Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1-Rearranged Non—Small-Cell Lung Cancer [published online ahead of print October 4, 2014]. N Engl J Med. doi:10.1056/NEJMoa1406766.